ABVC BioPharma Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Uttam Patil

Amministratore delegato

US$107.6k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.9yrs
Proprietà del CEO	0.5%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	6.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

Mar 13

Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Oct 05

ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

Sep 23

ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

Aug 18

ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

Aug 17

ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial

Jul 13

Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute

Jun 30

AMMINISTRATORE DELEGATO

Uttam Patil (38 yo)

1.9yrs

Mandato

US$107,623

Compensazione

Dr. Uttam Yashwant Patil, Ph D., is Chief Executive Officer of ABVC BioPharma, Inc. from June 21, 2023 and serves as its Interim Chief Financial Officer from March 05, 2025. Dr. Patil has served as the Chi...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Eugene Jiang	Chairman & Chief Business Officer	9.8yrs	US$415.24k	6.53% $ 1.0m
Tsung-Shann Jiang	Chief Scientific Officer	6.3yrs	US$353.75k	2.85% $ 449.9k
Tsang-Ming Jiang	Director	7.5yrs	Nessun dato	0.28% $ 44.1k
Norimi Sakamoto	Independent Director	7.5yrs	Nessun dato	0.28% $ 43.9k
Yen-Hsin Chou	Independent Director	7.5yrs	Nessun dato	0.28% $ 44.1k
Yoshinobu Odaira	Independent Director	6.3yrs	Nessun dato	0.38% $ 60.6k
Susanna Cunningham-Rundles	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Chang-Jen Jiang	Director	7.5yrs	Nessun dato	0.28% $ 44.0k
Che-Wei Hsu	Independent Director	3yrs	Nessun dato	0.28% $ 43.6k
Shuling Jiang	Director	3yrs	Nessun dato	5.77% $ 911.5k
Hsin-Hui Miao	Independent Director	2.9yrs	Nessun dato	0.28% $ 43.6k
Yu-Min Chung	Independent Director	2.8yrs	Nessun dato	0.28% $ 43.5k

6.3yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ABVC sono considerati esperti (durata media dell'incarico 6.3 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/05/04 16:44
Prezzo dell'azione a fine giornata	2025/05/02 00:00
Guadagni	2025/03/31
Guadagni annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

ABVC BioPharma, Inc. è coperta da 2 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Jason McCarthy	Maxim Group
Marla Marin	Zacks Small-Cap Research

ABVC BioPharma Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

ABVC BioPharma, Inc., Annual General Meeting, Jun 03, 2025

ABVC BioPharma, Inc. Announces Executive Changes

ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024

ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024

ABVC BioPharma, Inc., Annual General Meeting, Jan 16, 2024

ABVC Biopharma, Inc. Appoints Dr. Uttam Yashwant Patil as Chief Executive Officer

Recent updates

ABVC Biopharma Receives a Letter from the Listing Qualifications Staff of Nasdaq

ABVC BioPharma, Inc., Annual General Meeting, Jun 03, 2025

ABVC BioPharma, Inc. announced delayed annual 10-K filing

ABVC BioPharma, Inc. Announces Executive Changes

Nasdaq Grants 180-Day Grace Period to ABVC Biopharma to Regain Compliance with Bid Price Requirement

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

ABVC BioPharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

ABVC BioPharma, Inc. announced delayed 10-Q filing

ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024

ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024

ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC

ABVC BioPharma, Inc., Annual General Meeting, Jan 16, 2024

ABVC BioPharma, Inc. Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma, Inc. announced delayed 10-Q filing

Abvc Biopharma, Inc. Announces Completion of Subject Recruitment for Interim Analysis on Adhd Phase Iib Clinical Study

ABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement

ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $1.75 million.

ABVC BioPharma, Inc. announced that it expects to receive $1.75 million in funding

Nasdaq Grants ABVC Biopharma an Extension to Comply with Listing Rule 5550(b)(1)

ABVC Biopharma, Inc. Appoints Dr. Uttam Yashwant Patil as Chief Executive Officer

ABVC BioPharma Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders' Equity Requirement

ABVC BioPharma, Inc. Announces Vitargus®? Phase II Study Receives Ethical Approval At Sydney Eye Hospital in Australia

First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.20 loss in 1Q 2022)

ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

ABVC BioPharma Receives an Additional 180 Days, Until August 14, 2023, to Comply with Rule 5550(a)(2)

Abvc Biopharma Abv-1505 Adhd Phase Iia Results Presented At 2023 Apsard Conference

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

ABVC BioPharma, Inc. Receives Thai FDA Approval for Phase II Vitargus Study Protocol

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder

ABVC BioPharma, Inc. Announces That Cedars-Sinai Medical Center Institutional Review Board (IRB) Approves Institution Joining the Phase I Study of ABV-1601

ABVC BioPharma, Inc. Announces Vitargus(R) Phase II Study Plan Approved by Hrec in Australia

Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Abvc Biopharma, Inc. Provides Adhd Phase Ii Part 2 Clinical Study Update and Announces Ucsf Institutional Review Board Approval

ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

ABVC BioPharma Receives Non-Compliance Letter from Nasdaq

ABVC BioPharma, Inc. Provides Vitargus Update

ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

ABVC BioPharma, Inc. Provides Vitargus Update

ABVC BioPharma, Inc. Announces Board Changes

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial

ABVC BioPharma, Inc. Announces the Vitargus® Phase II Clinical Study Protocol Approval by the Central Research Ethics Committee (CREC) of the National Research Council of Thailand

Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute

ABVC BioPharma, Inc. Submitts Vitargus(R) Phase II Study Plan to Australia HREC

Abvc Biopharma, Inc. Appoints Ms. Hsin-Hui Miao to its Board

ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study

ABVC BioPharma, Inc. Announces Board Elections

First quarter 2022 earnings: EPS and revenues miss analyst expectations

ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $4.22 million.

ABVC BioPharma, Inc. Announces ADHD Phase II Part 2 Clinical Study First Subject

ABVC Biopharma Announces Streamlined Vitargus® Manufacturing Process

Insufficient new directors

ABVC BioPharma, Inc. Announces Vitargus Phase II Clinical Study Investigator Meeting

Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

ABVC BioPharma, Inc. Selects Additional Vitargus Phase II Study Sites

Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?

High number of new directors

Third quarter 2021 earnings released: US$0.067 loss per share (vs US$0.095 loss in 3Q 2020)

High number of new directors

High number of new directors

High number of new directors

ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study

High number of new directors